Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
Find a Doctor
Find a doctor at The Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center or Johns Hopkins Community Physicians.
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
Tiny Nanoparticles Could Make Big Impact for Patients in Need of Cornea Transplant - 03/09/2015
Tiny Nanoparticles Could Make Big Impact for Patients in Need of Cornea Transplant
- Medicine-loaded nanoparticles show promise for humans needing corneal transplants.
- Tiny nanoparticles may be solution for medicine compliance.
- Animal study gives patients, family members and clinicians hope for more easily managing medicine after eye surgery.
There are about 48,000 corneal transplants done each year in the U.S., compared to approximately 16,000 kidney transplants, according to the National Kidney Foundation, and 2,100 heart transplants, according to the U.S. Department of Health and Human Services' Organ Transplantation Network. Out of the 48,000 corneal transplants done, 10 percent of them end up in rejection, largely due to poor medication compliance. This costs the health care system and puts undue strain on clinicians, patients and their families.
Johns Hopkins Medicine researchers may have discovered a way to prevent rejection by using biodegradable nanoparticles that release needed medication into the eye after surgery. This discovery could solve the decades-old issue of medicine compliance and help patients achieve corneal transplant success.
“Medicine compliance is a major challenge in patient care,” says Walter Stark, M.D., chief of the Division of Cornea, Cataract and External Eye Diseases at Johns Hopkins. “About 60 to 80 percent of patients don’t take medicine the way they are supposed to.”
In an animal study being published in the March 10 issue of the Journal of Controlled Release, researchers looked into ways to alleviate the strain of adhering to a post-surgery treatment regimen that is sometimes hard to manage.
Rats that underwent a corneal graft surgery were randomly divided into four groups and were given various treatments. One group was injected weekly for nine weeks with a safe, biodegradable nanoparticle loaded with corticosteroids for timed release of medicine. The other three groups received weekly injections of saline, placebo nanoparticles and free dexamethasone sodium phosphate aqueous solution after surgery, respectively.
Treatments were given until the graft was clinically deemed as failed or until the nine-week test period concluded. Researchers looked at corneal transparency, swelling and growth of new blood vessels to decide if a graft had failed. For rats that received the nanoparticle loaded with corticosteroids, 65 percent of the treatment remained in the eye and did not leak within one week of the surgery. The concentration of the treatment also remained stronger than in the other three treatment groups. Additionally, there were no signs of swelling, and the cornea was clear throughout the test period. There were also far fewer instances of unwanted growth of new blood vessels in this group.
Two weeks after surgery, rats that received the placebo nanoparticle and saline injections had severe swelling, opaque corneas and unwanted growth of new blood vessels, all indicating graft failure. After four weeks, rats that received free dexamethasone sodium phosphate aqueous solution all had graft failure as well. The only group that showed successful corneal transplant was the group of rats that received the corticosteroid-loaded nanoparticle injections. The grafts were still viable in 100 percent of these rats.
“Corneal grafts are not easy to come by, and a lot of testing and time goes into ensuring the safe use of a graft for cornea transplant,” says Qingguo Xu, Ph.D., a research associate at the Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins Medicine. “This is why we want to do a better job at making sure corneal transplants don’t end up in rejection, and our study illustrates a potentially better way.”
The steroid-loaded nanoparticle treatment group showed no signs of corneal transplant rejection. “That’s 100 percent efficacy, a very promising finding,” says Justin Hanes, Ph.D., director of the Center for Nanomedicine. “This type of treatment may also help prevent corneal transplant rejection in humans while making medicine adherence much easier on patients and their families.”
The nanoparticle loaded with medication could eliminate the need for a patient to remember to take their medicine — often multiple doses per hour — after a surgery, alleviating compliance risk. These types of drug delivery systems could be paired with other drugs and used in other conditions, such as glaucoma, macular degeneration and corneal ulcers, among others. The research team intends to continue the collaboration between engineering and medicine to look further into better ways to treat eye diseases.
Additional authors include Qing Pan, Nicholas J. Boylan, Nicholas W. Lamb, David Emmert, Jeh-Chang Yang, Li Tang, Tom Feflin, Saeed Alwadani and Charles G Eberhart.
Funding of this study came from the Raymond Kwok Family Research Fund. This work was also partially funded by a grant from the King Khaled Eye Specialist Hospital of Saudi Arabia and the Eye Bank Association of America/Richard Lindstrom Research Grant 2012.